Targeting BET bromodomain proteins in cancer: The example of lymphomas.

Pharmacology & Therapeutics
Filippo SprianoFrancesco Bertoni

Abstract

The Bromo- and Extra-Terminal domain (BET) family proteins act as "readers" of acetylated histones and they are important transcription regulators. BRD2, BRD3, BRD4 and BRDT, part of the BET family, are important in different tumors, where upregulation or translocation often occurs. The potential of targeting BET proteins as anti-cancer treatment originated with data obtained with a first series of compounds, and there are now several data supporting BET inhibition in both solid tumors and hematological malignancies. Despite very positive preclinical data in different tumor types, the clinical results have been so far moderate. Using lymphoma as an example to review the data produced in the laboratory and in the context of the early clinical trials, we discuss the modalities to make BET targeting more efficient both generating novel generation of compounds and by exploring the combination with small molecules affecting various signaling pathways, BCL2, or DNA damage response signaling, but also with additional epigenetic agents and with immunotherapy. We also discuss the mechanisms of resistance and the toxicity profiles so far reported.

Citations

Sep 4, 2020·Blood Advances·Filippo SprianoFrancesco Bertoni
Feb 19, 2021·Journal of Medicinal Chemistry·Yi ZhangYuanxiang Wang
Mar 26, 2021·Journal of Medicinal Chemistry·Junping PeiLiang Ouyang
Jul 13, 2021·World Journal of Stem Cells·Harpreet K MandhairRamin Radpour

❮ Previous
Next ❯

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.